<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363797">
  <stage>Registered</stage>
  <submitdate>8/03/2013</submitdate>
  <approvaldate>20/03/2013</approvaldate>
  <actrnumber>ACTRN12613000310763</actrnumber>
  <trial_identification>
    <studytitle>N-Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD): A Double-Blind, Randomised, Placebo-Controlled Clinical Trial</studytitle>
    <scientifictitle>N-Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD) </scientifictitle>
    <utrn>U1111-1140-0513 </utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obsessive Compulsive Disorder (OCD)</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>N-acetyl cysteine (NAC): 500mg capsules taken orally - 1 capsule twice daily for 1 week, 2 capsules twice daily for the second week and 3 capsules twice daily (3g/day) for the remaining 13 weeks (total 16 weeks). </interventions>
    <comparator>Placebo capsules taken in the same manner as the NAC, identical in appearance, which do not contain N-acetyl cysteine or any active component.   </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Severity in symptoms will be measured with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</outcome>
      <timepoint>Reviewed at baseline, week 4, 8, 12 and 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Fulfil DSM-IV TR diagnostic criteria for OCD 
Self reported OCD will require a diagnosis from a physician
Score 16+ on the Y-BOCS at the time of recruitment
No other treatment, or be on stable treatment i.e. minimum 4 weeks of treatment or minimum of 12 weeks if a new treatment (e.g. SSRI, CBT)
Female participants of child bearing age or sexually active are required to be using effective contraception

 </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known or suspected serious medical disorder i.e. cancer, organ failure
Patients undergoing current psychological programs for their OCD (a four week wash out period will be required for eligibility) 
Bipolar I, schizophrenia, epilepsy
Gastrointestinal ulcers
Pregnancy or breastfeeding
History of hypersensitivity or intolerance to NAC
Patients taking 100 micrograms of selenium or 500 IU of vitamin E</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>For potential subjects, a pre screening telephone interview will be completed to assess if they meet the criteria for the trial. If so, they will be invited to meet the clinician at the Melbourne Clinic for a baseline screening interview. By signing a consent form at this interview, which outlines the nature of the trial, and meeting the criteria at the baseline interview, they will become officially enrolled in the research project. The participants will be allocated a number and then randomised into the treatment group or placebo via a computer software program. The clinician will be unaware of which group the participant will be enrolled in. A person outside the project will then code the treatments and maintain the key to this code until data collection is completed. </concealment>
    <sequence>Subjects will be randomised into one of two groups determined by computerised random allocation using their participant number.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods>The primary efficacy analysis will assess average treatment group differences for the primary outcome measure (Y-BOCS) using a mixed-effects model, repeated measures approach (MMRM). Results from the analysis of dichotomous data (e.g. demographics data) will be presented as proportions (e.g. Relative Risks), with 95% confidence interval, and Fishers Exact p-value where appropriate. Non-parametric statistics will be used when assumptions for parametric methods are violated. Effect sizes will be calculated using Cohens d. All tests of treatment effects will be conducted using a two-sided alpha level of 0.05 and 95% confidence intervals. Data analysed via SPSS 20.0.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>27/03/2013</anticipatedstartdate>
    <actualstartdate>13/03/2013</actualstartdate>
    <anticipatedenddate>1/08/2014</anticipatedenddate>
    <actualenddate>10/12/2014</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize>44</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>8/04/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Melbourne Clinic - Richmond</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Melbourne Clinic</primarysponsorname>
    <primarysponsoraddress>130 Church St Richmond, Melbourne, Victoria, 3121</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Bioceuticals</sponsorname>
      <sponsoraddress>Unit 16 37-41 O'Riordan St, 
Alexandria, NSW
2015</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to investigate the efficacy and safety of adjunctive N-acetylcysteine (NAC) in the treatment of adults (n=80) with DSM-IV diagnosed OCD in a 16-week randomised, placebo-controlled trial. The primary outcome will be between group differences the severity of OCD symptoms on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).</summary>
    <trialwebsite />
    <publication>N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study; Jerome Sarris, Georgina Oliver, David A. Camfield, Olivia M. Dean, Nathan Dowling, Deidre J. Smith, Jenifer Murphy, Ranjit Menon, Michael Berk, Scott Blair-West, Chee H. Ng; CNS Drugs (2015) 29: 801.

Sarris, J., Oliver, G., Camfield, D. A., &amp; Dean, O. M. (2016). Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in Obsessive-Compulsive Disorder. Clinical Psychological Science, 4(6), 1104-1111.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Melbourne Clinic HREC</ethicname>
      <ethicaddress>130 Church St, Richmond, 
Melbourne, 
VIC, 3121</ethicaddress>
      <ethicapprovaldate>11/02/2013</ethicapprovaldate>
      <hrec>219</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jerome Sarris</name>
      <address>The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121 </address>
      <phone>+61404083393</phone>
      <fax />
      <email>jsarris@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Gina Oliver</name>
      <address>The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121 </address>
      <phone>+61 3 9487 4659</phone>
      <fax />
      <email>georgina.oliver@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Gina Oliver</name>
      <address>The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121 </address>
      <phone>+61 3 9487 4659</phone>
      <fax />
      <email>georgina.oliver@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Gina Oliver</name>
      <address>The Melbourne Clinic, 2 Salisbury st, Richmond, VIC, 3121 </address>
      <phone>+61 3 9487 4659</phone>
      <fax />
      <email>georgina.oliver@unimelb.edu.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>